Investment Managers Series Trust II - Tradr 2X Long ASTS Daily ETF
US ˙ BATS

Introduction

This page provides a comprehensive analysis of the known insider trading history of James S J Manuso. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate James S J Manuso has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:IRD / Opus Genetics, Inc. Director 261,763
US:KTRA / Kintara Therapeutics, Inc. Director 0
US:RSPI / RespireRx Pharmaceuticals Inc. President and CEO, Director 608,704
US:ASTX / Investment Managers Series Trust II - Tradr 2X Long ASTS Daily ETF Chief Executive Officer, Director 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by James S J Manuso. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases ASTX / Investment Managers Series Trust II - Tradr 2X Long ASTS Daily ETF - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ASTX / Investment Managers Series Trust II - Tradr 2X Long ASTS Daily ETF. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ASTX / Investment Managers Series Trust II - Tradr 2X Long ASTS Daily ETF Insider Trades
Insider Sales ASTX / Investment Managers Series Trust II - Tradr 2X Long ASTS Daily ETF - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ASTX / Investment Managers Series Trust II - Tradr 2X Long ASTS Daily ETF. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2013-05-14 ASTX MANUSO JAMES S J 29,500 5.8400 29,500 5.8400 172,280 730
2013-05-02 ASTX MANUSO JAMES S J 38,000 5.8700 38,000 5.8700 223,060
2013-03-08 ASTX MANUSO JAMES S J 40,000 4.4000 40,000 4.4000 176,000

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ASTX / Investment Managers Series Trust II - Tradr 2X Long ASTS Daily ETF Insider Trades
Insider Purchases IRD / Opus Genetics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ASTX / Investment Managers Series Trust II - Tradr 2X Long ASTS Daily ETF. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2022-05-20 OCUP MANUSO JAMES S J 5,000 1.9900 5,000 1.9900 9,950 334 6.3800 21,950 220.60
2021-11-18 OCUP MANUSO JAMES S J 2,000 3.5000 2,000 3.5000 7,000
2020-11-19 OCUP MANUSO JAMES S J 4,434 4,434

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

IRD / Opus Genetics, Inc. Insider Trades
Insider Sales IRD / Opus Genetics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ASTX / Investment Managers Series Trust II - Tradr 2X Long ASTS Daily ETF. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

IRD / Opus Genetics, Inc. Insider Trades
Insider Purchases RSPI / RespireRx Pharmaceuticals Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ASTX / Investment Managers Series Trust II - Tradr 2X Long ASTS Daily ETF. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2017-09-13 RSPI MANUSO JAMES S J 1,097 110 96 2.1000
2015-08-28 CORX MANUSO JAMES S J 11,887,779 70,972

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

RSPI / RespireRx Pharmaceuticals Inc. Insider Trades
Insider Sales RSPI / RespireRx Pharmaceuticals Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ASTX / Investment Managers Series Trust II - Tradr 2X Long ASTS Daily ETF. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

RSPI / RespireRx Pharmaceuticals Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by James S J Manuso as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-05-02 2025-04-30 4 IRD Opus Genetics, Inc.
Common Stock
A - Award 79,504 261,763 43.62
2025-01-06 2025-01-02 4 IRD Opus Genetics, Inc.
Common Stock
A - Award 50,222 182,259 38.04
2024-10-22 3 KTRA Kintara Therapeutics, Inc.
Common Stock
0
2024-06-13 2024-06-11 4 OCUP Ocuphire Pharma, Inc.
Common Stock
A - Award 41,143 132,037 45.26
2024-01-03 2024-01-01 4 OCUP Ocuphire Pharma, Inc.
Common Stock
A - Award 22,090 90,894 32.11
2023-06-08 2023-06-06 4 OCUP Ocuphire Pharma, Inc.
Common Stock
A - Award 10,976 68,804 18.98
2023-04-21 2023-04-19 4 OCUP Ocuphire Pharma, Inc.
Common Stock
A - Award 2,819 57,828 5.12
2023-01-12 2023-01-11 4 OCUP Ocuphire Pharma, Inc.
Common Stock
A - Award 18,544 55,009 50.85
2022-10-12 2022-10-11 4 OCUP Ocuphire Pharma, Inc.
Common Stock
X - Other 787 36,465 2.21 0.00 0 4
2022-07-06 2022-07-01 4 OCUP Ocuphire Pharma, Inc.
Common Stock
A - Award 14,108 35,678 65.41
2022-05-24 2022-05-20 4 OCUP Ocuphire Pharma, Inc.
Common Stock
P - Purchase 5,000 21,570 30.18 1.99 9,950 42,924
2021-11-22 2021-11-18 4 OCUP Ocuphire Pharma, Inc.
Common Stock
P - Purchase 2,000 16,570 13.73 3.50 7,000 57,995
2021-06-09 2021-06-07 4 OCUP Ocuphire Pharma, Inc.
Stock Option (right to buy)
A - Award 20,000 20,000
2020-11-25 2020-11-19 4 OCUP Ocuphire Pharma, Inc.
Series B Warrant (right to buy)
P - Purchase 787 787
2020-11-25 2020-11-19 4 OCUP Ocuphire Pharma, Inc.
Series A Warrant (right to buy)
P - Purchase 6,697 6,697
2020-11-25 2020-11-19 4 OCUP Ocuphire Pharma, Inc.
Common Stock
P - Purchase 4,434 14,570 43.75
2020-11-13 2020-11-11 4 OCUP Ocuphire Pharma, Inc.
Stock Option (right to buy)
A - Award 5,000 5,000
2020-11-09 2020-11-05 4 OCUP Ocuphire Pharma, Inc.
Stock Option (right to buy)
A - Award 52,825 52,825
2020-11-09 2020-11-05 4 OCUP Ocuphire Pharma, Inc.
Stock Option (right to buy)
A - Award 35,663 35,663
2020-11-09 2020-11-05 4 OCUP Ocuphire Pharma, Inc.
Common Stock
A - Award 10,136 10,136
2017-12-12 2017-12-09 4 RSPI RespireRx Pharmaceuticals Inc.
Common Stock Options (to purchase shares of Common Stock)
J - Other 608,704 608,704
2017-12-12 2017-09-13 4 RSPI RespireRx Pharmaceuticals Inc.
Common Stock Warrants (right to buy)
P - Purchase 2,195 2,195
2017-12-12 2017-09-13 4 RSPI RespireRx Pharmaceuticals Inc.
Common Stock
P - Purchase 1,097 74,252 1.50
2017-07-05 2017-06-30 4 RSPI RespireRx Pharmaceuticals Inc.
Common Stock Options (to purchase shares of Common Stock)
A - Award 50,000 50,000
2017-01-20 2017-01-18 4 RSPI RespireRx Pharmaceuticals Inc.
Common Stock Options (to purchase shares of Common Stock)
A - Award 75,000 75,000
2016-04-11 2016-04-07 4 RSPI RespireRx Pharmaceuticals Inc.
Common Stock Warrants (right to buy)
J - Other 11,887,779 11,887,779
2016-04-11 2016-04-07 4 RSPI RespireRx Pharmaceuticals Inc.
Common Stock Warrants (right to buy)
J - Other -23,775,558 0 -100.00
2016-04-11 2016-04-07 4 RSPI RespireRx Pharmaceuticals Inc.
Common Stock
J - Other 11,887,779 23,775,558 100.00
2016-04-04 2016-03-31 4 RSPI RespireRx Pharmaceuticals Inc.
Common Stock Options (to purchase shares of Common Stock)
A - Award 26,500,000 26,500,000
2016-04-04 2016-02-04 4 RSPI RespireRx Pharmaceuticals Inc.
Common Stock Warrants (right to buy)
J - Other 2,630,000 2,630,000
2015-08-31 2015-08-28 4 CORX CORTEX PHARMACEUTICALS INC/DE/
Common Stock Warrants (right to buy)
P - Purchase 23,775,558 23,775,558
2015-08-31 2015-08-28 4 CORX CORTEX PHARMACEUTICALS INC/DE/
Common Stock
P - Purchase 11,887,779 11,887,779
2015-08-20 2015-08-18 4 CORX CORTEX PHARMACEUTICALS INC/DE/
Common Stock Options (to purchase shares of Common Stock)
A - Award 80,000,000 80,000,000
2015-08-20 2015-08-18 4 CORX CORTEX PHARMACEUTICALS INC/DE/
Common Stock Options (to purchase shares of Common Stock)
A - Award 5,081,300 5,081,300
2015-08-20 3 CORX CORTEX PHARMACEUTICALS INC/DE/
No securities are beneficially owned
0
2013-10-16 2013-10-11 4 ASTX Astex Pharmaceuticals, Inc
Employee Stock Option (Right to buy)
D - Sale to Issuer -360,000 0 -100.00
2013-10-16 2013-10-11 4 ASTX Astex Pharmaceuticals, Inc
Employee Stock Option (Right to buy)
D - Sale to Issuer -360,000 0 -100.00
2013-10-16 2013-10-11 4 ASTX Astex Pharmaceuticals, Inc
Employee Stock Option (Right to buy)
D - Sale to Issuer -360,000 0 -100.00
2013-10-16 2013-10-11 4 ASTX Astex Pharmaceuticals, Inc
Employee Stock Option (Right to buy)
D - Sale to Issuer -360,000 0 -100.00
2013-10-16 2013-10-11 4 ASTX Astex Pharmaceuticals, Inc
Employee Stock Option (Right to buy)
D - Sale to Issuer -800,000 0 -100.00
2013-10-16 2013-10-11 4 ASTX Astex Pharmaceuticals, Inc
Employee Stock Option (Right to buy)
D - Sale to Issuer -360,000 0 -100.00
2013-10-16 2013-10-11 4 ASTX Astex Pharmaceuticals, Inc
Employee Stock Option (Right to buy)
D - Sale to Issuer -1,200,000 0 -100.00
2013-10-16 2013-10-11 4 ASTX Astex Pharmaceuticals, Inc
Employee Stock Option (Right to buy)
D - Sale to Issuer -360,000 0 -100.00
2013-10-16 2013-10-11 4 ASTX Astex Pharmaceuticals, Inc
Employee Stock Option (Right to buy)
D - Sale to Issuer -360,000 0 -100.00
2013-10-16 2013-10-11 4 ASTX Astex Pharmaceuticals, Inc
Employee Stock Option (Right to buy)
D - Sale to Issuer -1,000,000 0 -100.00
2013-10-16 2013-10-11 4 ASTX Astex Pharmaceuticals, Inc
Employee Stock Option (Right to buy)
D - Sale to Issuer -200,000 0 -100.00
2013-10-16 2013-10-11 4 ASTX Astex Pharmaceuticals, Inc
Employee Stock Option (Right to buy)
D - Sale to Issuer -250,000 0 -100.00
2013-10-16 2013-10-11 4 ASTX Astex Pharmaceuticals, Inc
Employee Stock Option (Right to buy)
D - Sale to Issuer -250,000 0 -100.00
2013-10-16 2013-10-11 4 ASTX Astex Pharmaceuticals, Inc
Common Stock
U - Other -70 0 -100.00
2013-10-16 2013-10-11 4 ASTX Astex Pharmaceuticals, Inc
Common Stock
U - Other -13,900 0 -100.00
2013-09-06 2013-09-04 4 ASTX Astex Pharmaceuticals, Inc
Director Stock Option (Right to buy)
M - Exercise -7,500 0 -100.00
2013-09-06 2013-09-04 4 ASTX Astex Pharmaceuticals, Inc
Common Stock
M - Exercise 7,500 13,900 117.19 5.69 42,675 79,091
2013-05-15 2013-05-14 4 ASTX Astex Pharmaceuticals, Inc
Director Stock Option (Right to buy)
M - Exercise -29,500 0 -100.00
2013-05-15 2013-05-14 4 ASTX Astex Pharmaceuticals, Inc
Common Stock
S - Sale -29,500 6,400 -82.17 5.84 -172,280 37,376
2013-05-15 2013-05-14 4 ASTX Astex Pharmaceuticals, Inc
Common Stock
M - Exercise 29,500 35,900 460.94 4.03 118,885 144,677
2013-05-06 2013-05-02 4 ASTX Astex Pharmaceuticals, Inc
Director Stock Option (Right to buy)
M - Exercise -30,500 29,500 -50.83
2013-05-06 2013-05-02 4 ASTX Astex Pharmaceuticals, Inc
Director Stock Option (Right to buy)
M - Exercise -7,500 0 -100.00
2013-05-06 2013-05-02 4 ASTX Astex Pharmaceuticals, Inc
Common Stock
S - Sale -38,000 6,400 -85.59 5.87 -223,060 37,568
2013-05-06 2013-05-02 4 ASTX Astex Pharmaceuticals, Inc
Common Stock
M - Exercise 38,000 44,400 593.75 4.03 153,140 178,932
2013-04-03 2013-04-01 4 ASTX Astex Pharmaceuticals, Inc
Employee Stock Option (Right to buy)
A - Award 360,000 360,000
2013-03-12 2013-03-08 4 ASTX Astex Pharmaceuticals, Inc
Director Stock Option (Right to buy)
M - Exercise -40,000 0 -100.00
2013-03-12 2013-03-08 4 ASTX Astex Pharmaceuticals, Inc
Common Stock
S - Sale -40,000 6,400 -86.21 4.40 -176,000 28,160
2013-03-12 2013-03-08 4 ASTX Astex Pharmaceuticals, Inc
Common Stock
M - Exercise 40,000 46,400 625.00 2.46 98,400 114,144
2012-09-28 2012-09-28 4 ASTX Astex Pharmaceuticals, Inc
Employee Stock Option (Right to buy)
A - Award 50,000 50,000
2012-04-04 2012-04-02 4 ASTX Astex Pharmaceuticals, Inc
Employee Stock Option (Right to buy)
A - Award 360,000 360,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)